This guidance relates to the tablet formulation of Lynparza – in a capsule form the drug is recommended by NICE as an option for women with relapsed, platinum-sensitive ovarian, fallopian tube ...

The trial was assessing Lynparza, a 300mg tablet taken twice daily compared with physician’s choice of standard of care chemotherapy in patients with HER2-negative metastatic breast cancer ...

AstraZeneca (NASDAQ:AZN) and Merck (NYSE:MRK) said long-term data from a Phase 3 study showed that 87.5% of patients treated with their breast cancer drug Lynparza were still alive six years later ...